Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
magazine2022 should prove a pivotal year for GlaxoSmithKline
GlaxoSmithKline (GSK) £17.96
Gain to date: 36%
Original entry point: Buy at £13.21 on 5 November 2020
Investor sentiment towards GlaxoSmithKline (GSK) has continued to improve based upon a combination of self-help and agitation from activist investor Elliott Advisors.
Meanwhile a more challenging economic backdrop makes the defensive qualities of healthcare more attractive and so the shares have been in demand.
GlaxoSmithKline made a strong start to the 2022 financial year with first quarter revenue growing 34% while earnings per share was 43% ahead at 32.8p.
Its consumer healthcare division Haleon will be demerged from the group in July and floated on the UK stock market.
Over the medium term, Haleon is targeting organic sales growth of between 4% and 6% and a sustainable moderate expansion of operating margin from the 22.8% achieved in 2021.
Following the demerger GlaxoSmithKline will become a focused biopharmaceutical and vaccines business. It will soon change its name to GSK.
It hopes to deliver more than 5% annualised revenue growth and more than 10% annualised growth in adjusted operating profit over the next five years.
SHARES SAYS: We remain positive on GlaxoSmithKline.
Important information:
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell Youinvest.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
Issue contents
Feature
Great Ideas
- Find out why WH Smith remains an exciting Covid recovery play
- A tight power market continues to drive earnings upgrades at Drax
- Why we’re sticking with formidable long-run performer Fidelity Special Values
- 2022 should prove a pivotal year for GlaxoSmithKline
- Shares in comparison website owner Moneysupermarket are too cheap to ignore
- This is how to find a winning combination of cheap stocks and inflation protection
